Preimplantation genetic diagnosis for chromosome rearrangements – one blastomere biopsy versus two blastomere biopsy
Preimplantation Genetic Diagnosis (PGD) has proven to be a useful reproductive option for carriers of some chromosome rearrangements. The data presented in this study compares the impact of one versus two blastomere biopsy on the likelihood of achieving a PGD result, as well as the effect on subsequent embryo development and clinical outcomes.
IVF-PGD couples had either one or two blastomeres biopsied from all embryos with ≥7 blastomeres on day 3 post oocyte collection. These blastomeres were assessed for the specific chromosome rearrangement using Fluorescent In-situ Hybridisation (FISH). Further embryo development was monitored on days 4 and 5. Clinical outcomes were assessed retrospectively.
The data shows that statistically more embryos achieved a PGD result following two blastomere biopsy, compared with one blastomere biopsy (92 % versus 88 %, respectively). Furthermore it was found that embryo development and clinical outcomes were similar between the two biopsy groups.
Based on this analysis it appears that the biopsy of two blastomeres from embryos with ≥7 blastomeres on day 3 is a valid and successful approach for couples presenting for IVF-PGD for a chromosome rearrangement.
KeywordsIn vitro Fertilisation (IVF) Preimplantation Genetic Diagnosis (PGD) Fluorescent In Situ Hybridisation (FISH) Embryo biopsy Translocation
The authors wish to thank the following IVF clinics who participate in transport PGD through Monash IVF, for kindly agreeing to provide requested data on embryo development and clinical outcomes: Concept Fertility Centre, Hollywood Fertility Centre, Fertility Associates, Fertility Plus, Fertility Specialists of Western Australia, Monash IVF, Next Generation Fertility, Pivet and Repromed.
- 5.Emiliani S, Gonzalez-Merino E, Van den Bergh M, Delneste D, Englert Y, Abramowicz M. Correlation between fluorescence in-situ hybridization analyses and in-vitro development to blastocyst stage of embryos from Robertsonian translocation (13;14) carriers. Hum Reprod. 2002;17:2957–62.PubMedCrossRefGoogle Scholar
- 6.Goossens V, De Rycke M, De Vos A, Staessen C, Michiels A, Verpoest W, Van Steirteghem A, Bertrand C, Liebaers I, Devroey P, Sermon K. Diagnostic efficiency, embryo development and clinical outcome after the biopsy of one or two blastomeres for preimplantation genetic diagnosis. Hum Reprod. 2007;23:481–92.PubMedCrossRefGoogle Scholar
- 8.Harton GL, Magli MC, Lundin K, Montag M, Lemmen J, Harper JC. ESHRE PGD Consortium/Embryology Special Interest Group – best practice guidelines for polar body and embryo biopsy for preimplanation genetic diagnosis/screening (PGD/PGS). Hum Reprod. 2010;0:1–6.Google Scholar
- 11.Sandalinas M, Sadowy S, Alikani M, Calderon G, Cohen J, Munne S. Developmental ability of chromosomally abnormal human embryos to develop to the blastocyst stage. Hum Reprod. 2001;16:1954–8.Google Scholar
- 13.Van de Velde H, De Vos A, Sermon K, Staessen C, De Rycke M, Van Assche E, Lissens W, Vandervorst M, Van Ranst H, Liebaers I, Van Steirteghem A. Embryo implantation after biopsy of one or two cells from cleavage-stage embryos with a view to preimplantation genetic diagnosis. Prenat Diagn. 2000;20:1030–7.PubMedCrossRefGoogle Scholar